The advisors on Veraxa’s merger with Voyager Acquisition Corp
Walder Wyss advised Zurich-based Veraxa Biotech on its merger with Voyager Acquisition Corp, a Cayman Islands publicly traded Special Purpose Acquisition Company (SPAC), which was instead represented by Bratschi.
The context
The companies signed an agreement on 23 April 2025, with the closing planned for Q4 2025. Pursuant to the operation Veraxa values at up to USD 1.64 billion. Upon completion of the deal, Veraxa Biotech will become a Nasdaq-listed company.
The Walder Wyss team
Partners Marius Breier (tax, pictured above – left) and Thiemo Sturny (corporate/M&A, pictured above -right) led the Walder Wyss team on the matter, working alongside senior associate Martina Madonna-Quadri (corporate/M&A), partner Maurus Winzap (tax), associate Claude Schmid (tax), senior associate Erik Lanz (corporate/M&A) and senior associate Gustaf Heintz (employment).
The Bratschi team
Partner Claudio Bazzi (corporate/M&A, pictured) led the Bratschi team, working with partners Marco Rizzi (corporate/M&A), Michael Barrot (tax), Adrian Bieri (IP), and Felix Kesselring (life sciences). Associates Daniel Mosimann (corporate/M&A), Stephanie Caprani-Pontes (corporate/M&A) and Rico Dufner (tax) further contributed to the effort.
